No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on Fulcrum Therapeutics, Maintains $17 Price Target
Buy Rating Affirmed for Fulcrum Therapeutics: Licensing Deal With Sanofi and Promising Phase 3 Study
Fulcrum Therapeutics Is Maintained at Outperform by Oppenheimer
Fulcrum Therapeutics Is Maintained at Outperform by Oppenheimer
Express News | Oppenheimer Maintains Outperform on Fulcrum Therapeutics, Lowers Price Target to $14
Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Express News | Fulcrum Therapeutics Inc : Leerink Partners Raises Target Price to $16 From $14